Compare TG Therapeutics Inc (TGTX) vs Block Inc (XYZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Block Inc — how do they compare? TG Therapeutics Inc trades at $55.24 (market cap $8.16B), while Block Inc trades at $77.25 (market cap $45.20B). The key difference: Block Inc is far larger — about 5.5× TG Therapeutics Inc's market cap, and Block Inc is more actively traded (8,386,094 versus 1,735,121). Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Block Inc for 78 Days on average.
| TGTX | XYZ | |
|---|---|---|
Market Cap | $8.16B | $45.20B |
Volume | 1,735,121 | 8,386,094 |
Sector | Health | Technology |
52-Week High | $59.06 | $84.85 |
52-Week Low | $26.94 | $49.04 |
Typical Hold Time | 16 Days | 78 Days |
Enterprise Value | $8.37B | $40.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Block (XYZ) trades at $77.09, up 1.34% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q1 and Q2 2026 earnings beats but faces profitability challenges with a net margin of just 1.43%. Recent developments include expanding Square and Cash App partnerships with Apple and Workday, while pursuing a national trust bank charter to reduce third-party banking costs.
The stock offers 26% upside to the $97.47 consensus target with strong analyst support (77% buy ratings), though high P/E of 134.34 raises valuation concerns. Key risks include declining net income margins, insider selling activity, and competitive fintech pressures. The upcoming Q3 2026 earnings report on November 3rd will be critical for validating growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Block Inc
Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →
